CERRITOS, Calif.--(BUSINESS WIRE)--KabaFusion, a leading provider of specialty acute and chronic home infusion therapies, today announced its support for the Preserving Patient Access to Home Infusion Act, which was introduced in the United States Congress by a bipartisan coalition of members from both the Senate and the House of Representatives on March 12, 2020, and urges Congress to approve this legislation expeditiously.
Home infusion therapy allows high-risk and vulnerable patients, including those with compromised immune systems, to receive medically necessary treatments in the safety and comfort of their own home. The Preserving Patient Access to Home Infusion Act ensures continued coverage for certain home infusion medications under Medicare Part B and implements the professional services benefit in a manner consistent with what Congress intended in the bipartisan 21st Century Cures Act.
“KabaFusion applauds the introduction of the Preserving Patient Access to Home Infusion Act by Congress, as this legislation will protect patient access to vital home infusion treatments under Medicare,” said Dr. Sohail Masood, founder and Chief Executive Officer of KabaFusion. “With the rapidly advancing coronavirus pandemic, access to home infusion therapies is increasingly necessary to continue treatment plans for patients and can help keep some patients at home when hospital resources and capacity are strained. With home infusion therapies, vulnerable patients can receive high-quality and cost-effective treatments in the safety of their own home.”
Connie Sullivan, BSPharm, President and CEO of the National Home Infusion Association (NHIA) added, “NHIA similarly commends the Preserving Patient Access to Home Infusion Act and calls for the swift passage of this important legislation. Amid the COVID-19 public health crisis, it is more important than ever to ensure that patients can receive home-based treatments. We applaud this legislation and thank Dr. Masood in advocating for these vital services for high-risk and vulnerable patients.”
This Preserving Patient Access to Home Infusion Act was introduced in Congress on March 12, 2020 by Representatives Eliot Engel (D-NY), Terri Sewell (D-AL), Fred Upton (R-MI) and Kenny Marchant (R-TX), and Senators Mark Warner (D-VA) and Tim Scott (R-SC).
KabaFusion was founded by Dr. Sohail Masood, Pharm D., in 2010 and operates 28 home infusion specialty pharmacies strategically located in California, Alabama, Arkansas, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Jersey, New York, North Carolina, Pennsylvania, Texas, Virginia and Wyoming. KabaFusion is guided by a commitment to positive clinical outcomes and excellence in specialty acute and chronic therapies including intravenous immunoglobulin (IVIG). The company is dedicated to working proactively with patients, healthcare practitioners and payors to provide comprehensive support before, during and after treatment. For more information, visit www.KabaFusion.com.